FDA警告信披露印度药品生产商严重卫生与物料管理缺陷,公司被列入进口禁令66-40
Shocking Conditions at Indian pharmaceutical Manufacturer
FDA对一家印度OTC及顺势疗法药品生产商的检查发现严重GMP违规,警告信列出生产和仓储区域的活体啮齿动物、鸟类、昆虫及霉样沉积等卫生问题。公司起初未回应483表,直到FDA在边境截停一批药品货运后才申请90天延期,FDA要求其开展全面整改并重新评估物料系统。美国经销商已发起产品召回,FDA于2025年3月31日将该公司列入进口禁令66-40,其产品暂停进口美国直至另行通知。
材料汇总FDA对一家印度OTC及顺势疗法药品生产商的检查缺陷、整改要求与进口禁令安排,便于读者对照警告信所列的卫生和物料管理问题。
The FDA inspection of an Indian manufacturer, which took place in December 2024, revealed serious violations of GMP requirements, in particular unsustainable hygienic conditions in the production and storage rooms. The FDA writes in the introduction that the manufacturer of OTC and homeopathic medicinal products had initially not responded to the inspection findings (Form 483), although the FDA had contacted the manufacturer several times. It was not until the FDA stopped a drug shipment at the border in March that the manufacturer requested a 90-day extension to respond to the FDA 483 form. Unacceptable hygiene deficienciesThe FDA's list of shocking manufacturing conditions in the Warning Letter makes impressive reading. Among other things, the inspectors found Live rodents and birds in storage areas for finished drug products and packaging materials Animal faeces and feathers on walls, floors and materials Black, mould-like deposits on ceilings above production equipment and on walls near open tanks and filling lines Insects in production areas Stray dogs near open access doors Production materials in dirty containers stored outdoorsThese conditions demonstrate a complete failure of basic hygiene standards and pose a significant risk to drug safety. The FDA requires a comprehensive remediation plan, measures for technical and organisational control of the facilities as well as procedures for pest control and maintenance. GMP violations in material managementThe Indian manufacturer did not test incoming materials for identity, relied solely on unverified CoAs from suppliers and did not operate a quarantine or release system. In addition, a critical raw material was used that was known to have been supplied with incorrect labelling - yet no identity testing was performed.The FDA requires a complete reassessment of the material system and evidence of appropriate quality testing (chemical and microbiological) as well as a requirement for identity testing of each batch. In addition, a retrospective risk assessment is to be carried out for affected batches. Inadequate quality systemAccording to the FDA, the company's quality department showed serious weaknesses. It lacked basic SOPs (e.g. for deviations, cleaning, employee training), there was no process validation, no complete batch documentation, no adequate sampling and testing plans and no qualified cleaning procedures. The FDA requires a complete remediation programme to restore GMP compliance, including process validation and qualification of all equipment.Recall and import banDue to the violations and the company's lack of response to official enquiries, a recall of the products was initiated by the US distributor. In addition, the FDA placed the company on Import Alert 66-40 on 31 March 2025 - all of the company's products may no longer be imported into the USA until further notice. The detailed Warning Letter to the Indian manufacturer can be found on the FDA website.
来源:ECA GMP News · gmp-compliance.org